Description: MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
Home Page: www.medincell.com
3 rue des Frères Lumière
Jacou,
34830
France
Phone:
33 4 67 02 13 67
Officers
| Name | Title |
|---|---|
| Mr. Christophe Douat | CEO & Chairman of Exec. Board |
| Mr. Jaime Arango | CFO & Member of Exec. Board |
| Dr. Joel Richard | Member of Exec. Board |
| Mr. Franck Pouzache | Chief People Officer |
| Mr. David Heuze | Head of Communication & IR and Member of Exec. Board |
| Mr. Adolfo Lopez Noriega | Head of Research & Member of Exec. Board |
| Julie Alimi | Head of Legal |
| Mr. Sebastien Enault | Chief Bus. Officer |
| Ms. Helen Martin | Head of Alliance Management |
| Ms. Quiterie De Beauregard | Head of Portfolio |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 27.5888 |
| Price-to-Sales TTM: | 20.9652 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 151 |